Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
temsirolimus + capecitabine
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Temsirolimus + capecitabine is a combination of two pharmaceutical agents used primarily in oncology. Temsirolimus is a small molecule kinase inhibitor that targets the mammalian target of rapamycin (mTOR), leading to inhibition of cell growth, proliferation, and survival by blocking mTOR signaling pathways. It is approved for advanced renal cell carcinoma and has been investigated in other cancers[1][2][5][8]. Capecitabine is an oral prodrug that is metabolized to 5-fluorouracil (5-FU) in vivo; 5-FU inhibits thymidylate synthase and disrupts DNA and RNA synthesis, resulting in apoptosis of rapidly dividing cells. Capecitabine is indicated for various gastrointestinal cancers, including colorectal and pancreatic cancer, as well as breast cancer[3][4]. The combination may be used off-label or investigationally for synergistic antitumor effects.
- Brand names
- XelodaTorisel
- Other names
- sirolimus derivative (for temsirolimus)5-fluorouracil prodrug (for capecitabine)
02
Targets
TS (Thymidylate synthase)Mechanistic target of rapamycin complex 1
Beyond the preview
Go deeper on temsirolimus + capecitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on temsirolimus + capecitabine.